Maya Mimuro

Dr. Maya Mimuro

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2017 in Neuropathology
Verified
Journal Article
Closed access
PDF file
MMMaya Mimuro
Maya Mimuro
MYMari Yoshida
Mari Yoshida
SKShigeki Kuzuhara
Shigeki Kuzuhara
YKYasumasa Kokubo
Yasumasa Kokubo

9 May 2013 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
YRYuichi Riku
Yuichi Riku
TITakeshi Ikeuchi
Takeshi Ikeuchi
HYHiroyo Yoshino
Hiroyo Yoshino
MMMaya Mimuro
Maya Mimuro
KMKazuo Mano
Kazuo Mano
MYMari Yoshida
Mari Yoshida
Background: Infantile neuroaxonal dystrophy (INAD) is a rare autosomal-recessive neurodegenerative disorder. Patients with INAD usually show neurological symptoms with infant onset and die in childhood. Recently, it was reported that mutations in the PLA2G6 gene cause INAD, but neuropathological analysis of genetically confirmed individuals with neuroaxonal dystrophy has been limited. Results: Here, we report a Japanese individual with neuroaxonal dystrophy associated with compound heterozygous mutations in the PLA2G6 gene. A novel splice-site mutation resulting in skipping and missense mutations (p.R538C) in exon 9 was identified in the patient. This patient initially presented with cerebellar ataxia at the age of 3 years, which was followed by symptoms of mental retardation, extrapyramidal signs, and epileptic seizure. The patient survived until 20 years of age. Neuropathological findings were characterized by numerous axonal spheroids, brain iron deposition, cerebellar neuronal loss, phosphorylated alpha-synuclein-positive Lewy bodies (LBs), and phosphorylated-tau-positive neurofibrillary tangles. In particular, LB pathology exhibited a unique distribution with extremely severe cortical involvement. Conclusions: Our results support a genetic clinical view that compound heterozygous mutations with potential residual protein function are associated with a relatively mild phenotype. Moreover, the severe LB pathology suggests that dysfunction of the PLA2G6 gene primarily contributes to LB formation.

11 December 2014 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
STShinsui Tatsumi
Shinsui Tatsumi
TUToshiki Uchihara
Toshiki Uchihara
IAIkuko Aiba
Ikuko Aiba
Yasushi IwasakiYasushi Iwasaki
Yasushi Iwasaki
MMMaya Mimuro
Maya Mimuro
MYMari Yoshida
Mari Yoshida
Pretangles are defined under the light microscope as diffuse and granular tau immunoreactivity in neurons in tissue from patients with Alzheimer disease (AD) or corticobasal degeneration (CBD) and are considered to be a premature stage before neurofibrillary tangle formation. However, the ultrastructure of pretangles remains to be described. To clarify the similarities and differences between pretangles from patients with AD and CBD (AD-pretangles and CBD-pretangles, respectively), we examined cortical pretangles in tissue from patients with each of diseases. For direct light and electron microscopic (LM/EM) correlation of the pretangles, we used quantum dot nanocrystals (QDs) with dual fluorescent and electron-dense properties. We first identified tau-labeled pretangles on fluorescence LM and subsequently examined the same neurons on EM. Energy dispersive X-ray spectrometry (EDX) color mapping identified selenium (Se) and cadmium (Cd) as elementary components of QDs and highlighted each QD particle clearly against gray-scale EM images. With these methods, we were successful for the first time in demonstrating accurately that LM-defined pretangles are tau-positive straight filaments sparsely distributed throughout neuronal cytoplasm and neurites in both AD and CBD at the EM level. Notably, AD-pretangles showed a strong tendency to form fibrillary tangles even at an early stage, whereas pretangles or Pick-like inclusions in tissue from patients with CBD did not even at an advanced stage. In conclusion, AD-pretangles and CBD-pretangles showed essential differences at the EM level.

30 June 2015 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
PDF file
Yasushi IwasakiYasushi Iwasaki
Yasushi Iwasaki
AAAkio Akagi
Akio Akagi
MMMaya Mimuro
Maya Mimuro
TKTetsuyuki Kitamoto
Tetsuyuki Kitamoto
MYMari Yoshida
Mari Yoshida

12 September 2019 in Neuropathology
Verified
Journal Article
Open access
PDF file
MMMaya Mimuro
Maya Mimuro
MYMari Yoshida
Mari Yoshida
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neurodegenerative disorders that show parkinsonism as their main symptom. Both PSP and CBD are sporadic tauopathies associated with hyperphosphorylated four‐repeat tau aggregation in neurons and glial cells. The characteristic pathologies of PSP are midbrain atrophy and the appearance of tufted astrocytes and globose‐type neurofibrillary tangles. PSP shows severe degeneration in the globus pallidus, substantia nigra, subthalamic nucleus, and cerebellar dentate nuclei. Conversely, the characteristic pathologies of CBD are cortical atrophy and the appearance of astrocytic plaques and argyrophilic threads. CBD is associated with severe degeneration in the cerebral white matter, substantia nigra, and globus pallidus. Clinical symptoms depend on the topographical distribution and severity of degeneration rather than on the type of aggregated protein or inclusions. PSP and CBD present clinically differential diagnostic difficulties because of their overlapping pathological distributions.